Edwards Lifesciences (NYSE:EW) Given New $73.00 Price Target at Piper Sandler

Edwards Lifesciences (NYSE:EW) had its price objective increased by Piper Sandler from $70.00 to $73.00 in a report published on Wednesday morning,Benzinga reports. Piper Sandler currently has a neutral rating on the medical research company’s stock.

A number of other equities analysts also recently commented on the stock. Robert W. Baird dropped their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Barclays increased their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. The Goldman Sachs Group upped their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Finally, Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Up 0.3 %

EW opened at $76.23 on Wednesday. The stock has a market cap of $44.96 billion, a price-to-earnings ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm’s fifty day moving average is $72.58 and its 200 day moving average is $69.41.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, sell-side analysts forecast that Edwards Lifesciences will post 2.56 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

Several institutional investors and hedge funds have recently bought and sold shares of EW. Alpha Financial Partners LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at $693,000. Koshinski Asset Management Inc. purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at $396,000. Vontobel Holding Ltd. raised its position in Edwards Lifesciences by 5.7% in the 3rd quarter. Vontobel Holding Ltd. now owns 439,106 shares of the medical research company’s stock valued at $28,977,000 after purchasing an additional 23,560 shares during the last quarter. nVerses Capital LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at $792,000. Finally, Trust Co. of Vermont raised its position in Edwards Lifesciences by 36.1% in the 3rd quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 801 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.